Supernus Pharmaceuticals (SUPN) Short-term Investments (2012 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Short-term Investments of $192.1 million for Q2 2026, down 49.16% year-over-year from $377.9 million in Q2 2025, and down 3.64% on a QoQ basis from $199.4 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Short-term Investments (2012 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Short-term Investments for 15 years, with the latest figure at $192.1 million in Q2 2026.
- Short-term Investments for Q2 2026 came in at $192.1 million, down 49.16% year-over-year; the trailing twelve-month figure through Jun 2026 was $192.1 million (down 49.16% YoY), and the FY2025 annual result was $180.2 million, down 53.1% from the prior year.
- Short-term Investments eased to $192.1 million in Q2 2026, from $199.4 million in the prior quarter.
- Over five years, Short-term Investments peaked at $384.3 million in Q4 2024 and troughed at $105.2 million in Q3 2023.
- A 5-year average of $240.4 million and a median of $197.9 million in 2022 frame the typical range for Short-term Investments.
- The widest annual swing landed in 2024, when Short-term Investments surged 253.16%; it then sank 65.07% in 2025.
- A 5-year view of Short-term Investments shows it stood at $368.2 million in 2022, then plunged by 51.16% to $179.8 million in 2023, then jumped by 113.7% to $384.3 million in 2024, then sank by 53.1% to $180.2 million in 2025, then climbed by 6.6% to $192.1 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $192.1 million in Q2 2026, $199.4 million in Q1 2026, and $180.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.11 Mn |
| Mar 31, 2026 | 199.37 Mn |
| Dec 31, 2025 | 180.22 Mn |
| Sep 30, 2025 | 129.79 Mn |
| Jun 30, 2025 | 377.89 Mn |
| Mar 31, 2025 | 347.74 Mn |
| Dec 31, 2024 | 384.28 Mn |
| Sep 30, 2024 | 371.54 Mn |
| Jun 30, 2024 | 295.10 Mn |
| Mar 31, 2024 | 234.34 Mn |
| Dec 31, 2023 | 179.82 Mn |
| Sep 30, 2023 | 105.20 Mn |
| Jun 30, 2023 | 126.95 Mn |
| Mar 31, 2023 | 170.13 Mn |
| Dec 31, 2022 | 368.21 Mn |
| Sep 30, 2022 | 280.30 Mn |
| Jun 30, 2022 | 187.36 Mn |
| Mar 31, 2022 | 196.49 Mn |
| Dec 31, 2021 | 136.25 Mn |
| Sep 30, 2021 | 228.57 Mn |